UNIVERSITY of WASHINGTON

HEOR FELLOWSHIP PROGRAM

Genentech
A Member of the Roche Group
The University of Washington and Genentech have established a Health Economics and Outcomes Research (HEOR) Fellowship Program. This two-year program will provide formal training and hands-on experience in the HEOR field.

The first year of the program will be spent at the University of Washington (Seattle, WA).

- The fellow will take core courses in biostatistics, health economics, outcomes research, policy, and epidemiology.
- The fellow will be awarded a Master’s Degree from the University upon completion of course requirements and a thesis project.

The second year will be spent at Genentech (South San Francisco, CA)

- The fellow will pursue hands-on training in strategically focused health economics and outcomes to support commercialization of Genentech’s products.
- The fellow will work closely with colleagues in the Evidence for Access organization, which is comprised of HEOR and Health Systems Researchers, in Genentech’s US Medical Affairs organization.

About the Program

David Veenstra, Pharm.D., Ph.D.,
Professor and Associate Director
The Comparative Health Outcomes,
Policy & Economics (CHOICE)
Institute
1959 NE Pacific Ave., H-375-P
Seattle, WA, 98195-7630
veenstra@uw.edu

Jennifer Whiteley, EdD, MSc., MA
Team Lead, HEOR
1 DNA Way
South San Francisco, CA, 94080
whiteley.jennifer@gene.com

Fellowship Directors

Program Information:
https://sop.washington.edu/choice
About The University of Washington

The University of Washington is a world-class leader in health sciences education and has been consistently listed in US News and World Report as one of the top 10 institutions for its graduate programs. The University is particularly noted for its strong research programs and since 1974 has received more federal funds for research and training than any other public university in the United States. It fosters a highly collegial atmosphere between departments and academic units, creating a particularly attractive environment for such partnerships between the public and private sectors.

The Comparative Health Outcomes, Policy & Economics (CHOICE) Institute is housed within the University of Washington School of Pharmacy, which boasts nearly 125 years of academic and research success. Faculty in the program (1) provide advanced research training for graduate students, post-doctoral fellows and clinicians (PharmDs, MDs); (2) conduct rigorous scientific research in economic evaluations and outcomes of pharmaceuticals and other health technologies, and (3) translate and disseminate the results of research into clinical practice and healthcare policy, with the goal of improving patient care.

CHOICE faculty participating in the fellowship have been chosen both for their dedication to teaching and their excellence in research. Each is trained either as a health economist or health services researcher and all have an extensive history of effective economic evaluations and pharmacoepidemiologic research.

University of Washington Program Faculty

Anirban Basu, PhD  
Professor and Stergachis Family Endowed Director of CHOICE

Denise Boudreau, PhD  
Affiliate Professor
  Kaiser Washington

Beth Devine, PharmD, MBA, PhD, FASHP  
Professor, Director of Graduate Programs

Josh Carlson, MPH, PhD  
Associate Professor

Louis P. Garrison, Jr., PhD  
Professor Emeritus

Ryan Hansen, PhD, PharmD  
Assistant Professor

Thomas K. Hazlet, PharmD, Dr. PH  
Associate Professor

Scott D. Ramsey, MD, PhD  
Professor

Sean D. Sullivan, BPharm, PhD  
Professor and Dean of School of Pharmacy

David L. Veenstra, PharmD, PhD  
Professor and Associate Director of CHOICE

Joseph Babigumira, MBChB, MS, PhD  
Adjunct Associate Professor

Aasthaa Bansal, PhD  
Assistant Professor

Caroline Bennette, MPH, PhD  
Affiliate Assistant Professor

Flatiron Health

Andy Stergachis, BPharm, PhD  
Professor and Associate Dean for Research, Graduate Programs and New Initiatives

Zachary Marcum, PharmD, PhD  
Assistant Professor
About Genentech

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years.

Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world’s leading biotech companies, with multiple products on the market and a promising development pipeline.

Our Purpose

**Doing now what patients need next**

We believe it’s urgent to deliver medical solutions right now – even as we develop innovations for the future. We are passionate about transforming patients’ lives. We are courageous in both decision and action. And we believe that good business means a better world.

That is why we come to work each day. We commit ourselves to scientific rigor, unassailable ethics, and access to medical innovations for all. We do this today to build a better tomorrow.

We are proud of who we are, what we do, and how we do it. We are many, working as one across functions, across companies, and across the world.
Genentech Evidence for Access Leadership Team

Jan Hansen  
Vice President

Emily Cook  
Operations

Danny Yeh  
Health Policy & Systems Research

Jennifer Whiteley  
HEOR

Elaine Yu  
HEOR

Jim Zazzali  
HEOR

Pictured above: HEOR Fellowship Mentors
Anisha Patel, PhD, MS
2010-2012
Johnson & Johnson / Rutgers University

Recent Manuscripts:


Sheila Shapouri, PharmD, MS
2016-2018
University of Washington / Allergan

Publications (manuscripts/abstracts) from Fellowship

• Shapouri S, Devine EB, Keyloun KR, Gillard PJ, Sabbatini AK, Bansal A. Predicting Hospitalizations and Returns to the Emergency Department 30-Days Post Emergency Department Discharge Among Patients with Acute Bacterial Skin and Skin Structure Infections. (In Progress)


Chris Wallick, PharmD, MS
2012-2014
University of Washington / Allergan

Recent Manuscripts:


